Drug Interactions between dalfopristin / quinupristin and Hecoria
This report displays the potential drug interactions for the following 2 drugs:
- dalfopristin/quinupristin
- Hecoria (tacrolimus)
Interactions between your drugs
tacrolimus dalfopristin
Applies to: Hecoria (tacrolimus) and dalfopristin / quinupristin
GENERALLY AVOID: Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, including certain agents that can cause prolongation of the QTc interval (e.g., cisapride, disopyramide, pimozide, quinidine, tacrolimus). High plasma levels of these agents have been rarely associated with ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes, as well as cardiac arrest and sudden death.
MANAGEMENT: Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of agents that may prolong the QTc interval, concomitant use with dalfopristin-quinupristin should be avoided if they are known to be substrates of CYP450 3A4.
References (1)
- (2001) "Product Information. Synercid (dalfopristin-quinupristin)." Rhone Poulenc Rorer
Drug and food/lifestyle interactions
tacrolimus food/lifestyle
Applies to: Hecoria (tacrolimus)
GENERALLY AVOID: Grapefruit and/or grapefruit juice may increase the plasma concentrations of tacrolimus. The proposed mechanism for the interaction is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. Although clinical data are lacking, this interaction may result in increased risk of serious adverse reactions such as nephro- and neurotoxicity, as well as other adverse effects associated with tacrolimus such as malignancies, infections, diabetes, hyperkalemia, hypertension, and QT prolongation.
GENERALLY AVOID: Alcohol may modify the rate of tacrolimus release from extended release formulations, thereby potentially increasing the risk of serious adverse reactions.
ADJUST DOSING INTERVAL: Coadministration with food decreases the rate and extent of tacrolimus absorption. This effect is greatest after a high-fat meal.
MANAGEMENT: Patients should avoid consumption of food or drink containing grapefruit during treatment with tacrolimus. Concomitant use of tacrolimus, especially extended release formulations, with alcohol should also be avoided. Tacrolimus extended release formulations should be administered on an empty stomach, at least 1 hour before or 2 hours after a meal, and tacrolimus immediate release formulations should be taken consistently every day with or without food.
References (18)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- Hooks MA (1994) "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother, 28, p. 501-11
- (2022) "Product Information. Adoport (tacrolimus)." Sandoz Ltd
- (2024) "Product Information. TACrolimus (Sandoz) (TACrolimus)." Sandoz Pty Ltd
- (2023) "Product Information. Prograf (tacrolimus)." Astellas Pharma US, Inc
- (2023) "Product Information. Astagraf XL (tacrolimus)." Astellas Pharma US, Inc
- (2025) "Product Information. Envarsus XR (tacrolimus)." Veloxis Pharmaceuticals
- (2024) "Product Information. Prograf (tacrolimus)." Astellas Pharma Canada Inc
- (2024) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Canada Inc
- (2024) "Product Information. Envarsus PA (tacrolimus)." Endo Operations LTD
- (2024) "Product Information. Dailiport (tacrolimus)." Sandoz Ltd
- (2025) "Product Information. Prograf (tacrolimus)." Astellas Pharma Ltd
- (2025) "Product Information. Envarsus (tacrolimus)." Chiesi Ltd
- (2025) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Ltd
- (2025) "Product Information. Modigraf (tacrolimus)." Astellas Pharma Ltd
- (2024) "Product Information. Advagraf XL (TACrolimus)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. proGRAF (TACrolimus)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. TACrolimus XR (Sandoz) (TACrolimus)." Sandoz Pty Ltd
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.